Exploring the added value of hospital-registry data for showing local service outcomes: cancers of the ovary, fallopian tube and peritoneum
- PMID: 30782891
- PMCID: PMC6367964
- DOI: 10.1136/bmjopen-2018-024036
Exploring the added value of hospital-registry data for showing local service outcomes: cancers of the ovary, fallopian tube and peritoneum
Abstract
Objectives: To explore the added value of hospital-registry data on invasive epithelial ovarian, tubal and peritoneal cancers.
Design: Historic cohort analyses.
Methods: Unadjusted and adjusted regression.
Setting: Major South Australian hospitals.
Participants: 1596 women (1984-2015 diagnoses).
Results: 5-Year and 10-year survival was 48% and 41%, respectively, equivalent to relative survival for Australia and the USA. After adjusting for age, clinical and geographic factors, risk of ovarian cancer death was 25% lower in 2010-2015 than 1984-1989. Women generally had surgical treatment (87%) in their first round of care. This was more common for younger patients (adjusted OR (95% CIs) 0.17 (0.04 to 0.65) for 80+ vs <40 years) and earlier International Federation of Gynecology and Obstetrics stages (adjusted OR 0.48 (0.13 to 1.78) for stage IIIB/C and 0.13 (0.04 to 0.45) for stage IV vs stage IA). Most (74%) had systemic therapy, which was more common for advanced stages (adjusted ORs >15.0 for stages III and IV vs stage IA). Few (9%) had radiotherapy. Women generally had systemic therapy (74%), without difference by service accessibility and socioeconomic disadvantage, suggesting equity. However, surgery was less common for residents of the most compared with least remote areas (adjusted OR 0.49 (0.24 to 0.99)); and more common prior to adjustment in the highest versus lowest socioeconomic category (unadjusted OR 1.55 (1.01 to 2.39)), but this elevation did not apply after adjustment (adjusted OR 0.19 (0.63 to 2.25)), with the difference largely explained by stage.
Conclusions: Hospital-registry data add value for assessing local service delivery. Equivalent survival to Australia-wide and USA survival, and temporal gains after adjusting for stage and other patient characteristics are reassuring. Survival gains may reflect therapeutic benefits of more extensive surgery and improved chemotherapy regimens.
Keywords: cancer registries; treatment and survival.
© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Conflict of interest statement
Competing interests: None declared.
Similar articles
-
Restaging and Survival Analysis of 4036 Ovarian Cancer Patients According to the 2013 FIGO Classification for Ovarian, Fallopian Tube, and Primary Peritoneal Cancer.Int J Gynecol Cancer. 2016 May;26(4):680-7. doi: 10.1097/IGC.0000000000000675. Int J Gynecol Cancer. 2016. PMID: 26937751
-
Population-based study of survival for women with serous cancer of the ovary, fallopian tube, peritoneum or undesignated origin - on behalf of the Swedish gynecological cancer group (SweGCG).Gynecol Oncol. 2017 Jan;144(1):167-173. doi: 10.1016/j.ygyno.2016.10.039. Epub 2016 Nov 3. Gynecol Oncol. 2017. PMID: 27817932
-
Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials.Lancet Oncol. 2018 Dec;19(12):1680-1687. doi: 10.1016/S1470-2045(18)30566-7. Epub 2018 Nov 6. Lancet Oncol. 2018. PMID: 30413383
-
Ovarian, fallopian tube and peritoneal cancer staging: Rationale and explanation of new FIGO staging 2013.Best Pract Res Clin Obstet Gynaecol. 2015 Aug;29(6):858-69. doi: 10.1016/j.bpobgyn.2015.03.006. Epub 2015 Mar 31. Best Pract Res Clin Obstet Gynaecol. 2015. PMID: 25890882 Review.
-
Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancer.Int J Gynecol Cancer. 2010 Aug;20(6):945-52. doi: 10.1111/IGC.0b013e3181dd0110. Int J Gynecol Cancer. 2010. PMID: 20683400 Review.
References
-
- Ferlay J, Soerjomataram I, Ervik M, et al. . GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer. 2013. http://globocan.iarc.fr (accessed 6 Apr 2017).
-
- Australian Institute of Health and Welfare (AIHW). Australian Cancer Incidence and Mortality (ACIM) books. Canberra: AIHW, 2013. http://www.aihw.gov.au/acim-books/ (Accessed 6 Apr 2017).
-
- Australian Institute of Health and Welfare. Cancer in Australia 2017. Cancer Series no. 101. Cat. No. CAN 100. Canberra: AIHW, 2017.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical